Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares dropped 2.7% during trading on Monday . The company traded as low as C$0.18 and last traded at C$0.18. Approximately 392,474 shares changed hands during trading, an increase of 57% from the average session volume of 250,480 shares. The stock had previously closed at C$0.18.
Theralase Technologies Stock Performance
The firm has a market cap of C$54.70 million, a price-to-earnings ratio of -13.21 and a beta of -0.57. The company has a quick ratio of 3.40, a current ratio of 1.37 and a debt-to-equity ratio of 22.13. The business has a 50 day moving average price of C$0.25 and a 200-day moving average price of C$0.27.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
- Five stocks we like better than Theralase Technologies
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
- D-Wave Has Momentum—What Does It Need to Keep It Going?
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
